RxDoctor Payments Data

Anas Karaman, MD

Family Medicine · Panama City, FLNPI 1407388325

Payments from drug & device makers

$1,043in general payments, 2019–2025

Across 40 payments — averaging $26.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Baxter Healthcare$190
  • Novo Nordisk$185
  • AbbVie$129
  • AstraZeneca$121
  • Astellas Pharma US Inc$100
  • Amgen$75
  • plus $242 from 7 others

What the payments were for

  • Food & beverage$94390%
  • Education$10010%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,043 in reported general payments places this provider in the 60th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$157,821
Medicare patients
373
Services billed
1,517

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide97$133,129
JardianceEmpagliflozin63$71,142
EliquisApixaban54$57,951
MounjaroTirzepatide47$53,820
JanuviaSitagliptin Phosphate37$51,373
MyrbetriqMirabegron33$32,006
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$25,685
TrulicityDulaglutide16$25,071
FarxigaDapagliflozin Propanediol17$14,820
Spiriva HandihalerTiotropium Bromide15$10,886
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$7,151
Gabapentin209$5,564
Combivent RespimatIpratropium/Albuterol Sulfate11$5,402
Advair DiskusFluticasone Propion/Salmeterol23$4,829
Omeprazole304$4,482

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$185$133,12997 claims
Lilly USA, LLCMounjaro, Trulicity$32$78,89163 claims
Boehringer IngelheimJardiance, Combivent Respimat$19$76,54474 claims
PfizerEliquis$74$57,95154 claims
GSKTrelegy Ellipta, Anoro Ellipta$15$32,83636 claims
Astellas Pharma US IncMyrbetriq$100$32,00633 claims
AstraZenecaFarxiga$121$14,82017 claims
AbbVieSynthroid$129$2,01023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Panama City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →